Combination therapy for HER2-positive advanced breast cancer
Part of Cancer, Skin clinical trials.
This study tests a combination of two or three targeted medicines (Inetetamab, Paclitaxel, with or without Pertuzumab) in people with HER2-positive advanced breast cancer. The goal is to see if this new treatment helps shrink tumors and control the disease better than existing options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- Your breast cancer is HER2-positive (a certain protein is present).
- Your cancer has spread to other parts of the body or come back and cannot be removed with surgery.
- You have not had anti-HER2 treatment for advanced cancer before, or if you had it as early treatment, you finished it more than 12 months ago.
- Your heart is working well (at least 50% of normal) and you are otherwise healthy enough for treatment.
- You do not have cancer that has spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
This trial tests a new combination of targeted therapies (inetetamab plus rapamycin) with chemotherapy for HER2-positive breast cancer that has spread or come back and has a specific genetic change (PAM pathway mutation). It aims to see if this combination can work better than current treatments for people whose cancer has progressed after trastuzumab.
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
Hear when a new Breast Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.